首页> 外文期刊>The American journal of hospice and palliative care >Central nervous system aspergillosis in an immunocompetent patient: cure in a hospice setting with very high-dose itraconazole.
【24h】

Central nervous system aspergillosis in an immunocompetent patient: cure in a hospice setting with very high-dose itraconazole.

机译:具有免疫功能的患者的中枢神经系统曲霉病:使用非常高剂量的伊曲康唑可以在临终关怀环境中治愈。

获取原文
获取原文并翻译 | 示例
       

摘要

Aspergillosis of the central nervous system (CNS) is a rare condition with exceedingly high mortality. This study describes the case of an immunocompetent 42-year-old man with a history of intravenous drug use and hepatitis C who developed multiple Aspergillus lesions in the cerebellum. Despite neurosurgery and antifungal therapy with amphotericin B, he had a protracted hospital course with multiple complications, eventually developing cognitive and motor impairment due to progressive cerebellar lesions. After transfer to hospice and palliative care service, oral itraconazole was escalated to 1600 mg/day with the hope of palliating headache, nausea, and cognitive impairment. Remarkably, the patient stabilized and improved over time. After 14 months, this unprecedented high-dose regimen was discontinued, and the patient was discharged home with only mild cerebellar motor impairment.
机译:中枢神经系统(CNS)的曲霉病是罕见病,死亡率极高。这项研究描述了一个具有免疫功能的42岁男性,该病例具有静脉内吸毒史和丙型肝炎,并在小脑中发展了多个曲霉病。尽管进行了神经外科手术和两性霉素B的抗真菌治疗,但他的医院病程漫长,并伴有多种并发症,最终由于进行性小脑病变而导致认知和运动障碍。转移到临终关怀和姑息治疗服务后,口服伊曲康唑剂量升至1600 mg /天,希望可以缓解头痛,恶心和认知障碍。值得注意的是,随着时间的推移,患者逐渐稳定并有所改善。 14个月后,这种前所未有的大剂量治疗方案被中止,患者出院回家,仅出现轻度小脑运动障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号